As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

SEOUL, Jan. 23 (Korea Bizwire) — Celltrion Inc.’s autoimmune disease treatment, SteQeyma, has been launched in five major ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Celltrion's ustekinumab biosimilar is now available in France, Italy, Spain, Britain and Germany after securing European ...

Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 Company ...

Celltrion focuses on the development of antibody-drug conjugates (ADCs) and multi-specific antibodies. The company's goal is to leap from a biosimilar stronghold to a global innovative drug ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...